DYNT · Dynatronics Corp - Financials
Annual line items from SEC XBRL filings, sourced from EDGAR's Company Facts API with fallback to the quarterly Financial Statement Data Sets. See issuer overview for Form 4 activity and 10-K signals.
Income Statement
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
| Revenue | $27.39M | $32.53M | $40.61M | $44.34M | $47.80M | $53.41M |
| Cost of Revenue | $21.38M | $24.90M | $30.46M | $33.67M | $34.91M | $38.31M |
| Gross Profit | $6.01M | $7.63M | $10.15M | $10.67M | $12.89M | $15.10M |
| R&D | - | - | - | - | $10.0K | $95.0K |
| SG&A | $8.46M | $9.91M | $15.00M | $15.43M | $16.65M | $18.09M |
| Total Operating Expenses | - | - | - | - | - | - |
| D&A | $487.0K | $685.4K | $726.4K | $733.6K | $852.7K | $1.01M |
| Operating Income | ($2.45M) | ($2.27M) | ($4.85M) | ($4.76M) | ($3.76M) | ($2.99M) |
| Interest Expense | $409.9K | $418.0K | $118.3K | $148.0K | $215.6K | $435.6K |
| Income Tax | $12.2K | $0 | $0 | $0 | ($10.0K) | ($10.1K) |
| Net Income | ($10.90M) | ($2.70M) | ($4.97M) | ($3.99M) | $2.00M | ($3.43M) |
| EPS - Basic | ($1.43) | ($1.00) | ($1.32) | - | - | - |
| EPS - Diluted | ($1.43) | ($1.00) | ($1.32) | - | - | - |
Balance Sheet
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
| Cash & Equivalents | $326.3K | $483.9K | $398.8K | $550.1K | $6.10M | $2.22M |
| Accounts Receivable | $2.80M | $3.44M | $3.72M | $5.42M | $5.64M | $4.89M |
| Inventory | $5.07M | $5.59M | $7.40M | $12.07M | $6.53M | $8.37M |
| Accounts Payable | $3.40M | $2.71M | $4.53M | $6.17M | - | - |
| Current Assets | $8.95M | $10.56M | $12.42M | $19.23M | $20.91M | $16.07M |
| Total Assets | $15.44M | $25.94M | $30.06M | $35.43M | $39.14M | $37.60M |
| Current Liabilities | $8.24M | $7.70M | $7.94M | $9.94M | $8.47M | $7.68M |
| Long-term Debt | - | - | - | $0 | $5.4K | $3.50M |
| Total Liabilities | $12.18M | $11.78M | $13.21M | $13.74M | $13.63M | $17.70M |
| Stockholders' Equity | $3.26M | $14.16M | $16.86M | $21.70M | $25.51M | $19.90M |
| Retained Earnings | ($40.51M) | ($28.91M) | ($25.48M) | ($19.82M) | ($15.09M) | ($16.35M) |
Cash Flow
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
| Operating Cash Flow | $300.6K | ($1.61M) | $371.1K | ($4.88M) | $383.0K | $3.09M |
| Investing Cash Flow | ($30.4K) | ($243.3K) | ($186.9K) | ($317.8K) | $1.53M | ($292.4K) |
| Financing Cash Flow | ($427.7K) | $1.84M | ($332.7K) | ($350.1K) | $2.02M | ($737.1K) |
| CapEx | $30.4K | $243.3K | $186.9K | $317.8K | $146.9K | $292.4K |
| Free Cash Flow | $270.1K | ($1.85M) | $184.3K | ($5.20M) | $236.1K | $2.80M |
Ratios
| Metric | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
| Profitability | ||||||
| Gross margin | 21.9% | 23.5% | 25.0% | 24.1% | 27.0% | 28.3% |
| Operating margin | -9.0% | -7.0% | -11.9% | -10.7% | -7.9% | -5.6% |
| EBITDA margin | -7.2% | -4.9% | -10.2% | -9.1% | -6.1% | -3.7% |
| Net margin | -39.8% | -8.3% | -12.2% | -9.0% | 4.2% | -6.4% |
| Free cash flow margin | 1.0% | -5.7% | 0.5% | -11.7% | 0.5% | 5.2% |
| FCF / Net income | -0.02 | 0.69 | -0.04 | 1.30 | 0.12 | -0.82 |
| R&D / Revenue | - | - | - | - | 0.0% | 0.2% |
| SG&A / Revenue | 30.9% | 30.5% | 36.9% | 34.8% | 34.8% | 33.9% |
| Effective tax rate | - | - | - | - | -0.5% | - |
| Return on assets | -70.6% | -10.4% | -16.5% | -11.3% | 5.1% | -9.1% |
| Return on equity | -334.2% | -19.1% | -29.5% | -18.4% | 7.8% | -17.2% |
| Return on invested capital | - | - | - | -17.3% | -14.7% | -10.1% |
| Liquidity | ||||||
| Current ratio | 1.09 | 1.37 | 1.56 | 1.94 | 2.47 | 2.09 |
| Quick ratio | 0.47 | 0.64 | 0.63 | 0.72 | 1.70 | 1.00 |
| Cash ratio | 0.04 | 0.06 | 0.05 | 0.06 | 0.72 | 0.29 |
| Leverage | ||||||
| Debt / Equity | - | - | - | 0.00 | 0.00 | 0.18 |
| Debt / Assets | - | - | - | 0.00 | 0.00 | 0.09 |
| Debt / EBITDA | - | - | - | - | - | - |
| Interest coverage | -6.0x | -5.4x | -41.0x | -32.1x | -17.4x | -6.9x |
| Equity multiplier | 4.73 | 1.83 | 1.78 | 1.63 | 1.53 | 1.89 |
| Liabilities / Assets | 0.79 | 0.45 | 0.44 | 0.39 | 0.35 | 0.47 |
| Efficiency | ||||||
| Asset turnover | 1.77 | 1.25 | 1.35 | 1.25 | 1.22 | 1.42 |
| Inventory turnover | 4.21 | 4.45 | 4.11 | 2.79 | 5.35 | 4.58 |
| Days sales outstanding | 37d | 39d | 33d | 45d | 43d | 33d |
| Days inventory outstanding | 87d | 82d | 89d | 131d | 68d | 80d |
| Days payable outstanding | 58d | 40d | 54d | 67d | - | - |
| Cash conversion cycle | 66d | 81d | 68d | 109d | - | - |
| Valuation | ||||||
| P / E | - | - | - | - | - | - |
| P / B | - | - | - | - | - | - |
| P / S | - | - | - | - | - | - |
| EV / EBITDA | - | - | - | - | - | - |
| Growth | ||||||
| Revenue growth (YoY) | -15.8% | -19.9% | -8.4% | -7.2% | -10.5% | -14.6% |
| Revenue CAGR (3y) | -14.8% | -12.0% | -8.7% | -10.8% | 10.2% | 14.3% |
| Revenue CAGR (5y) | -12.5% | -12.3% | 2.6% | 4.4% | 9.5% | 12.9% |
| Gross profit growth (YoY) | -21.3% | -24.8% | -4.9% | -17.2% | -14.7% | -21.3% |
| Operating income growth (YoY) | -7.9% | 53.1% | -2.0% | -26.5% | -25.6% | -276.0% |
| Net income growth (YoY) | -304.1% | 45.8% | -24.5% | - | - | -271.6% |
| EPS growth (YoY) | -43.0% | 24.2% | - | - | - | - |
| EPS CAGR (3y) | - | - | - | - | - | - |
| EPS CAGR (5y) | - | - | - | - | - | - |
| FCF growth (YoY) | - | - | - | - | -91.6% | 2654.2% |
| FCF CAGR (5y) | -37.3% | - | -18.7% | - | - | - |
| Book value growth (YoY) | -77.0% | -16.0% | -22.3% | -15.0% | 28.2% | -4.1% |
Sales by segment
From XBRL dimensional facts in the 10-K period ending 2025-06-30.
Product / service
$27.39M totalPhysical Therapy And Rehabilitation Products$15.15M · 55.3%
Orthopedic Soft Bracing Products$12.14M · 44.3%
Other Products$94.2K · 0.3%
Stability scores
Altman Z′
FY 2025 · bankruptcy risk
-0.80
Distress
Private-firm variant - uses book equity instead of market cap. > 2.90 safe · 1.23-2.90 grey · < 1.23 distress.
Piotroski F-score
FY 2025 · 9-point quality
3/9
Weak
- ✗Net income positive
- ✓Operating cash flow positive
- ✗ROA improved YoY
- ✓Cash flow > net income
- -Long-term debt decreased
- ✗Current ratio improved
- ✗No share dilution
- ✗Gross margin improved
- ✓Asset turnover improved
Peer comparison
Same SIC group: Surgical & Medical Instruments & Apparatus
Comparing DYNATRONICS CORP against the 5 most active filers in the same SIC group.